"Imatinib Mesylate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.
| Descriptor ID |
D000068877
|
| MeSH Number(s) |
D02.065.277.456 D02.241.223.100.100.435 D02.455.426.559.389.127.085.465 D03.383.606.405 D03.383.742.349
|
| Concept/Terms |
Imatinib Mesylate- Imatinib Mesylate
- Mesylate, Imatinib
- Imatinib Methanesulfonate
- Methanesulfonate, Imatinib
Imatinib- Imatinib
- Alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
|
Below are MeSH descriptors whose meaning is more general than "Imatinib Mesylate".
Below are MeSH descriptors whose meaning is more specific than "Imatinib Mesylate".
This graph shows the total number of publications written about "Imatinib Mesylate" by people in this website by year, and whether "Imatinib Mesylate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2018 | 2 | 0 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Imatinib Mesylate" by people in Profiles.
-
DIA-Based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia. Mol Cell Proteomics. 2022 02; 21(2):100187.
-
BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature. Microcirculation. 2020 10; 27(7):e12625.
-
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia. 2018 07; 32(7):1657-1669.
-
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood. 2018 07 19; 132(3):307-320.
-
Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells. J Exp Med. 2006 Dec 25; 203(13):2829-40.
-
[Requirements for the development of molecularly defined targeted therapy in oncology]. Med Klin (Munich). 2006 Aug 15; 101(8):617-23.
-
Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene. 2002 Aug 22; 21(37):5716-24.
MeSH information
